AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors.
Nanoscale
; 16(5): 2347-2360, 2024 Feb 01.
Article
en En
| MEDLINE
| ID: mdl-38113032
ABSTRACT
This article presents bioconjugates combining nanoparticles (AGuIX) with nanobodies (VHH) targeting Programmed Death-Ligand 1 (PD-L1, A12 VHH) and Cluster of Differentiation 47 (CD47, A4 VHH) for active tumor targeting. AGuIX nanoparticles offer theranostic capabilities and an efficient biodistribution/pharmacokinetic profile (BD/PK), while VHH's reduced size (15 kDa) allows efficient tumor penetration. Site-selective sortagging and click chemistry were compared for bioconjugation. While both methods yielded bioconjugates with similar functionality, click chemistry demonstrated higher yield and could be used for the conjugation of various VHH. The specific targeting of AGuIX@VHH has been demonstrated in both in vitro and ex vivo settings, paving the way for combined targeted immunotherapies, radiotherapy, and cancer imaging.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Nanopartículas
/
Gadolinio
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Nanoscale
Año:
2024
Tipo del documento:
Article
País de afiliación:
Francia